AI news ·
PhaseV validates GLP-1 adverse-event model on patient data
PhaseV’s causal ML model predicted weight change, side effects, and dropout in GLP-1 trials using early patient data, but independent clinical review is still needed.
PhaseV reported that its causal machine-learning model successfully predicted weight change, adverse events, and treatment dropout when tested against held-out patient trajectories from GLP-1 clinical data. The validation exercise focused on the model’s ability to forecast individual patient responses using only baseline information and early treatment observations.
The results are based on vendor-reported performance metrics. While the findings indicate the model can reproduce key outcomes on data it did not see during training, clinical teams would still need to conduct independent assessments before relying on the tool for dosing decisions in practice.
Source: https://dailyaibrief.com